Literature DB >> 15895832

Phosphothreonine-212 of Alzheimer abnormally hyperphosphorylated tau is a preferred substrate of protein phosphatase-1.

Abdur Rahman1, Inge Grundke-Iqbal, Khalid Iqbal.   

Abstract

We isolated and characterized several phosphoseryl/phosphothreonyl phosphatase activities (P1-P11) from frontal lobe of six autopsied human brains. Of these, PP1 (P3) was a major tau phosphatase. The enzyme required metal ions and was maximally activated by Mn2+. Western blots with antibodies to known protein phosphatases showed PP1 and PP2B immunoreactivity. However, the removal of PP2B by immunoabsorption or its inhibition with EGTA did not result in appreciable loss of P3 activity. These observations suggest that P3 was an enriched PPI. Dephosphorylation of Alzheimer disease hyperphosphorylated tau (AD P-tau) by PP1 was site-specific. PPI preferentially dephosphorylated pT212 (40%), pT217 (26%), pS262 (33%), pS396 (42%) and pS422 (31%) of AD P-tau. Dephosphorylation of tau at pT181, pS199, pS202, pT205, pS214, and pS404, was undetectable. Of the sites dephosphorylated, pT212 was only a substrate for PP1, as purified/enriched PP2A and PP2B from the same brains did not dephosphorylate this site.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15895832     DOI: 10.1007/s11064-005-2483-9

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  41 in total

1.  Indexing-based differential display--studies on post-mortem Alzheimer's brains.

Authors:  M Ryan; M Starkey; R Faull; P Emson; S Bahn
Journal:  Brain Res Mol Brain Res       Date:  2001-03-31

2.  Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease.

Authors:  C X Gong; T Lidsky; J Wegiel; L Zuck; I Grundke-Iqbal; K Iqbal
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

3.  Promotion of hyperphosphorylation by frontotemporal dementia tau mutations.

Authors:  Alejandra del C Alonso; Anna Mederlyova; Michal Novak; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  J Biol Chem       Date:  2004-06-09       Impact factor: 5.157

4.  Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice.

Authors:  S Kins; A Crameri; D R Evans; B A Hemmings; R M Nitsch; J Gotz
Journal:  J Biol Chem       Date:  2001-07-25       Impact factor: 5.157

5.  Phosphorylation affects the ability of tau protein to promote microtubule assembly.

Authors:  G Lindwall; R D Cole
Journal:  J Biol Chem       Date:  1984-04-25       Impact factor: 5.157

6.  Inhibition of PP-2A upregulates CaMKII in rat forebrain and induces hyperphosphorylation of tau at Ser 262/356.

Authors:  M Bennecib; C X Gong; I Grundke-Iqbal; K Iqbal
Journal:  FEBS Lett       Date:  2001-02-09       Impact factor: 4.124

7.  Dephosphorylation and deactivation of Ca2+/calmodulin-dependent protein kinase II in betaTC3-cells is mediated by Mg2+- and okadaic-acid-sensitive protein phosphatases.

Authors:  R A Easom; J L Tarpley; N R Filler; H Bhatt
Journal:  Biochem J       Date:  1998-01-15       Impact factor: 3.857

8.  Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and -2B.

Authors:  J Z Wang; C X Gong; T Zaidi; I Grundke-Iqbal; K Iqbal
Journal:  J Biol Chem       Date:  1995-03-03       Impact factor: 5.157

9.  New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry.

Authors:  D P Hanger; J C Betts; T L Loviny; W P Blackstock; B H Anderton
Journal:  J Neurochem       Date:  1998-12       Impact factor: 5.372

10.  Dephosphorylation of Alzheimer's disease abnormally phosphorylated tau by protein phosphatase-2A.

Authors:  C X Gong; I Grundke-Iqbal; K Iqbal
Journal:  Neuroscience       Date:  1994-08       Impact factor: 3.590

View more
  22 in total

1.  Mechanism of okadaic acid-induced neuronal death and the effect of estrogens.

Authors:  Kun Don Yi; Douglas F Covey; James W Simpkins
Journal:  J Neurochem       Date:  2008-11-28       Impact factor: 5.372

Review 2.  Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.

Authors:  Elliott J Mufson; Scott E Counts; Sylvia E Perez; Stephen D Ginsberg
Journal:  Expert Rev Neurother       Date:  2008-11       Impact factor: 4.618

Review 3.  Tau in neurodegenerative disease.

Authors:  Yong-Lei Gao; Nan Wang; Fu-Rong Sun; Xi-Peng Cao; Wei Zhang; Jin-Tai Yu
Journal:  Ann Transl Med       Date:  2018-05

Review 4.  Aβ Influences Cytoskeletal Signaling Cascades with Consequences to Alzheimer's Disease.

Authors:  Ana Gabriela Henriques; Joana Machado Oliveira; Liliana Patrícia Carvalho; Odete A B da Cruz E Silva
Journal:  Mol Neurobiol       Date:  2014-10-26       Impact factor: 5.590

Review 5.  Protein phosphatases and Alzheimer's disease.

Authors:  Steven P Braithwaite; Jeffry B Stock; Paul J Lombroso; Angus C Nairn
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

6.  Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.

Authors:  Jian-Zhi Wang; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Eur J Neurosci       Date:  2007-01       Impact factor: 3.386

Review 7.  Molecular and cellular mechanism of okadaic acid (OKA)-induced neurotoxicity: a novel tool for Alzheimer's disease therapeutic application.

Authors:  Pradip K Kamat; Shivika Rai; Supriya Swarnkar; Rakesh Shukla; Chandishwar Nath
Journal:  Mol Neurobiol       Date:  2014-04-08       Impact factor: 5.590

Review 8.  Tau and tauopathies.

Authors:  Gloria Lee; Chad J Leugers
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

9.  Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.

Authors:  Martín Gómez Ravetti; Osvaldo A Rosso; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

10.  Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation.

Authors:  M-L Selenica; H S Jensen; A K Larsen; M L Pedersen; L Helboe; M Leist; J Lotharius
Journal:  Br J Pharmacol       Date:  2007-10-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.